The use of databases, data mining and immunoinformatics in vaccinology: where are we?

Expert Opinion on Drug Discovery

Volumn 13, Issue 2, 2018, Pages 117-130

  Hegde, Nagendra R ^a   Gauthami, S ^b   Sampath Kumar, H M ^c   Bayry, Jagadeesh ^d  

^a National Institute of Animal Biotechnology   (India)

^b Ella foundation   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d INSERM   (France)

Author keywords

Adjuvant; antigen; data mining; immunoinformatics; structural biology; systems immunology; vaccine design

Indexed keywords

ANTIBODY; EPITOPE; IMMUNOLOGICAL ADJUVANT; VACCINE;

BIOINFORMATICS; DATA BASE; DATA MINING; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION; ANIMAL; BIOLOGY; COMPUTER SIMULATION; FACTUAL DATABASE; GENOMICS; IMMUNOLOGY; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROTEOMICS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATA MINING; DATABASES, FACTUAL; GENOMICS; HUMANS; PROTEOMICS; VACCINES; VACCINOLOGY;

EID: 85041178669     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2018.1413088     Document Type: Review

References (139)

1. Plotkin SLP., S.A. A short history of vaccination. In: Plotkin SAO, Orenstein W, Offit P, editor. Vaccines. 6th ed. Philadelphia (PA): Saunders; 2013. p. 1–13.
2. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol. 2007 Dec;25(12):1361–1366. PubMed PMID: 18066025.
3. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010 Jul;17(7):1055–1065. PubMed PMID: 20463105; PubMed Central PMCID: PMC2897268.
4. Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis. 2013 May;56(10):1458–1465. PubMed PMID: 23386629.
5. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012 Jun;54(11):1615–1617. PubMed PMID: 22437237; PubMed Central PMCID: PMC3348952.
6. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000 Oct;3(5):445–450. PubMed PMID: 11050440.
7. Moise L, Moss SF, De Groot AS. Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics. Expert Rev Vaccines. 2012 Sep;11(9):1031–1033. PubMed PMID: 23151160.
8. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010 Oct 29;33(4):530–541. PubMed PMID: 21029963; PubMed Central PMCID: PMC3320742.
9. Vaishnav N, Gupta A, Paul S, et al. Overview of computational vaccinology: vaccine development through information technology. J Appl Genet. 2015 Aug;56(3):381–391. PubMed PMID: 25534541.
10. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 24;124(4):783–801. PubMed PMID: 16497588.
11. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010 Feb;125(2Suppl 2):S24–32. PubMed PMID: 19932920; PubMed Central PMCID: PMC2832725.
12. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31: 443–473. PubMed PMID: 23298205; PubMed Central PMCID: PMC4026165.
13. Neefjes J, Jongsma ML, Paul P, et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Reviews Immunol. 2011 Nov 11;11(12):823–836. PubMed PMID: 22076556.
14. Rossjohn J, Gras S, Miles JJ, et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 2015;33:169–200, PubMed PMID: 25493333
15. Zuniga EI, Macal M, Lewis GM, et al. Innate and adaptive immune regulation during chronic viral infections. Annu Rev Virol. 2015 Nov;21:573–597. PubMed PMID: 26958929; PubMed Central PMCID: PMC4785831.
16. Bagnoli F, Baudner B, Mishra RP, et al. Designing the next generation of vaccines for global public health. Omics. 2011 Sep;15(9):545–566. PubMed PMID: 21682594.
17. Davies DH, Liang X, Hernandez JE, et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA. 2005 Jan 18;102(3):547–552. PubMed PMID: 15647345; PubMed Central PMCID: PMC545576.
18. Gaseitsiwe S, Valentini D, Mahdavifar S, et al. Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol. 2010 Jan;17(1):168–175. PubMed PMID: 19864486; PubMed Central PMCID: PMC2812096.
19. Jing L, Davies DH, Chong TM, et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol. 2008 Jul;82(14):7120–7134. PubMed PMID: 18480455; PubMed Central PMCID: PMC2446988.
20. Jing L, McCaughey SM, Davies DH, et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods. 2009 Aug 15;347(1–2):36–45. PubMed PMID: 19520082; PubMed Central PMCID: PMC2715169.
21. Liang L, Felgner PL. A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases. Curr Opin Infect Dis. 2015 Oct;28(5):438–445. PubMed PMID: 26237545; PubMed Central PMCID: PMC4666702.
22. Magnan CN, Zeller M, Kayala MA, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010 Dec 01;26(23):2936–2943. PubMed PMID: 20934990; PubMed Central PMCID: PMC2982151.
23. Vigil A, Davies DH, Felgner PL. Defining the humoral immune response to infectious agents using high-density protein microarrays. Future Microbiol. 2010 Feb;5(2):241–251. PubMed PMID: 20143947; PubMed Central PMCID: PMC2841399.
24. El-Manzalawy Y, Honavar V. Recent advances in B-cell epitope prediction methods. Immunome Res. 2010 Nov 03;6(Suppl 2):S2. PubMed PMID: 21067544; PubMed Central PMCID: PMC2981878.
25. Sun P, Ju H, Liu Z, et al. Bioinformatics resources and tools for conformational B-cell epitope prediction. Comput Math Methods Med. 2013;2013:943636 PubMed PMID: 23970944; PubMed Central PMCID: PMC3736542;2013:943636.
26. Blythe MJ, Flower DR. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Science. 2005 Jan;14(1):246–248. PubMed PMID: 15576553; PubMed Central PMCID: PMC2253337.
27. He L, Zhu J, Computational tools for epitope vaccine design and evaluation. PubMed PMID: 25837467; PubMed Central PMCID: PMC4456225. Curr Opin Virol. 2015 Apr;11:103–112.
28. Sela-Culang I, Ofran Y, Peters B. Antibody specific epitope prediction-emergence of a new paradigm. PubMed PMID: 25837466; PubMed Central PMCID: PMC4456244. Curr Opin Virol. 2015 Apr;11:98–102
29. Kringelum JV, Lundegaard C, Lund O, et al. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829. PubMed PMID: 23300419; PubMed Central PMCID: PMC3531324.
30. Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med. 2013 May 01;3(5):a012476. PubMed PMID: 23637311; PubMed Central PMCID: PMC3633180.
31. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006 Jul 18;103(29):10834–10839. PubMed PMID: 16825336; PubMed Central PMCID: PMC2047628.
32. Masignani V, Rappuoli R, Pizza M. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin Biol Ther. 2002 Dec 2;(8):895–905. PubMed PMID: 12517268.
33. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000 Mar 10;287(5459):1816–1820. PubMed PMID: 10710308.
34. Scarselli M, Arico B, Brunelli B, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med. 2011 Jul 13;3(91):91ra62. PubMed PMID: 21753121.
35. Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000 Mar 10;287(5459):1809–1815. PubMed PMID: 10710307.
36. Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Reviews Microbiol. 2012 Dec;10(12):807–813.
37. Giefing C, Meinke AL, Hanner M, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med. 2008 Jan 21;205(1):117–131. PubMed PMID: 18166586; PubMed Central PMCID: PMC2234372.
38. Lauer P, Rinaudo CD, Soriani M, et al. Genome analysis reveals pili in Group B Streptococcus. Science. 2005 Jul 01;309(5731):105. PubMed PMID: 15994549.
39. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005 Jul 01;309(5731):148–150. PubMed PMID: 15994562; PubMed Central PMCID: PMC1351092.
40. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis. 2009 Jan 01;199(1):108–115. PubMed PMID: 19086816.
41. Mora M, Bensi G, Capo S, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci USA. 2005 Oct 25;102(43):15641–15646. PubMed PMID: 16223875; PubMed Central PMCID: PMC1253647.
42. Nuccitelli A, Cozzi R, Gourlay LJ, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci USA. 2011 Jun 21;108(25):10278–10283. PubMed PMID: 21593422; PubMed Central PMCID: PMC3121859.
43. Rodriguez-Ortega MJ, Norais N, Bensi G, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol. 2006 Feb;24(2):191–197. PubMed PMID: 16415855.
44. Kalman S, Mitchell W, Marathe R, et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet. 1999 Apr;21(4):385–389. PubMed PMID: 10192388.
45. Stephens RS. Chlamydial genomics and vaccine antigen discovery. J Infect Dis. 2000 Jun;181(Suppl 3):S521–523. PubMed PMID: 10839752.
46. Thorpe C, Edwards L, Snelgrove R, et al. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine. 2007 Mar 08;25(12):2252–2260. PubMed PMID: 17275142.
47. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013 Nov 01;342(6158):592–598. PubMed PMID: 24179220; PubMed Central PMCID: PMC4461862.
48. McLellan JS, Yang Y, Graham BS, et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011 Aug;85(15):7788–7796. PubMed PMID: 21613394; PubMed Central PMCID: PMC3147929.
49. Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA. 2011 Jun 07;108(23):9619–9624. PubMed PMID: 21586636; PubMed Central PMCID: PMC3111287.
50. Graham BS. Vaccines against respiratory syncytial virus: the time has finally come. Vaccine. 2016 Jun 24;34(30):3535–3541. PubMed PMID: 27182820; PubMed Central PMCID: PMC4912855.
51. Krarup A, Truan D, Furmanova-Hollenstein P, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015 Sep 03;6:8143. PubMed PMID: 26333350; PubMed Central PMCID: PMC4569726.
52. Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA. 2017 Aug 29;114(35):E7348–E7357. PubMed PMID: 28807998.
53. Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015 Feb;16(2):170–177. PubMed PMID: 25501631; PubMed Central PMCID: PMC4445969.
54. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015 Apr 02;520(7545):109–113. PubMed PMID: 25581790.
55. Smith SA, de Alwis AR, Kose N, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio. 2013 Nov 19;4(6):e00873–13. PubMed PMID: 24255124; PubMed Central PMCID: PMC3870244.
56. Smith SA, de Alwis R, Kose N, et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis. 2013 Jun 15;207(12):1898–1908. PubMed PMID: 23526830; PubMed Central PMCID: PMC3654755.
57. Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015 Jul 30;162(3):493–504. PubMed PMID: 26189681; PubMed Central PMCID: PMC4758460.
58. Hegde NR, Maddur MS, Rao PP, et al. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: a perspective. Vaccine. 2009 Apr 06;27(16):2199–2201. PubMed PMID: 19189856.
59. Mateo R, Luna E, Mateu MG. Thermostable variants are not generally represented in foot-and-mouth disease virus quasispecies. J Gen Virol. 2007 Mar;88(Pt 3):859–864. PubMed PMID: 17325358.
60. Mateo R, Luna E, Rincon V,et al. Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol. 2008 Dec;82(24):12232–12240. PubMed PMID: 18829763; PubMed Central PMCID: PMC2593342.
61. Rincon V, Rodriguez-Huete A, Lopez-Arguello S, et al. Identification of the structural basis of thermal liability of a virus provides a rationale for improved vaccines. Structure. 2014 Nov 04;22(11):1560–1570. PubMed PMID: 25308865.
62. Scott KA, Kotecha A, Seago J, et al. SAT2 foot-and-mouth disease virus structurally modified for increased thermostability. J Virol. 2017 May 15;91(10):e02312-02316. PubMed PMID: 28298597; PubMed Central PMCID: PMC5411616
63. Scott KA, Rathogwa NM, Capozzo AV, et al. Evaluation of immune responses of stabilised SAT2 antigens of foot-and-mouth disease in cattle. Vaccine. 2017 Apr 18;35(40):5426-5433. PubMed PMID: 28431813.
64. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011 Aug 12;333(6044):850–856. PubMed PMID: 21798894.
65. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009 Apr 10;324(5924):246–251. PubMed PMID: 19251591; PubMed Central PMCID: PMC2758658.
66. Shriver Z, Trevejo JM, Sasisekharan R. Antibody-based strategies to prevent and treat influenza. Front Immunol. 2015;6:315. PubMed PMID: 26217334; PubMed Central PMCID: PMC4500096.
67. Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010 May 18; 1(1). PubMed PMID: 20689752; PubMed Central PMCID: PMC2912658
68. Sui J, Hwang WC, Perez S,et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar;16(3):265–273. PubMed PMID: 19234466; PubMed Central PMCID: PMC2692245.
69. Whittle JR, Zhang R, Khurana S, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA. 2011 Aug 23;108(34):14216–14221. PubMed PMID: 21825125; PubMed Central PMCID: PMC3161572.
70. Krammer F, Hai R, Yondola M,et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol. 2014 Mar;88(6):3432–3442. PubMed PMID: 24403585; PubMed Central PMCID: PMC3957929.
71. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013 Oct 3;3(5):521–530. PubMed PMID: 23978327; PubMed Central PMCID: PMC3804342.
72. Krammer F, Pica N, Hai R,et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013 Jun;87(12):6542–6550. PubMed PMID: 23576508; PubMed Central PMCID: PMC3676110.
73. Margine I, Krammer F, Hai R,et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 2013 Oct;87(19):10435–10446. PubMed PMID: 23903831; PubMed Central PMCID: PMC3807421.
74. Rusert P, Kouyos RD, Kadelka C,et al. Determinants of HIV-1 broadly neutralizing antibody induction. Nat Med. 2016 Nov;22(11):1260–1267. PubMed PMID: 27668936.
75. Saunders KO, Nicely NI, Wiehe K, et al. Vaccine elicitation of high mannose-dependent neutralizing antibodies against the V3-glycan broadly neutralizing epitope in nonhuman primates. Cell Rep. 2017 Feb 28;18(9):2175–2188. PubMed PMID: 28249163; PubMed Central PMCID: PMC5408352.
76. Azoitei ML, Correia BE, Ban YE, et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science. 2011 Oct 21;334(6054):373–376. PubMed PMID: 22021856.
77. McLellan JS, Correia BE, Chen M, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol. 2011 Jun 24;409(5):853–866. PubMed PMID: 21549714; PubMed Central PMCID: PMC3107930.
78. Crowther JR, Farias S, Carpenter WC,et al. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. J Gen Virol. 1993 Aug;74(Pt 8):1547–1553. PubMed PMID: 8393912.
79. Erdmann N, Du VY, Carlson J,et al. HLA class-II associated HIV polymorphisms predict escape from CD4+ T cell responses. PLoS Pathog. 2015 Aug;11(8):e1005111. PubMed PMID: 26302050; PubMed Central PMCID: PMC4547780.
80. Ferreira HL, Lambrecht B, van Borm S,et al. Identification of a dominant epitope in the hemagglutinin of an Asian highly pathogenic avian influenza H5N1 clade 1 virus by selection of escape mutants. Avian Dis. 2010 Mar;54(1 Suppl):565–571. PubMed PMID: 20521695.
81. Clementi N, Mancini N, Criscuolo E, et al. Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis. Methods Mol Biol. 2014;1131:427–446. PubMed PMID: 24515481.
82. Gallagher ES, Hudgens JW. Mapping protein-ligand interactions with proteolytic fragmentation, hydrogen/deuterium exchange-mass spectrometry. Methods Enzymol. 2016;566:357–404. PubMed PMID: 26791987.
83. Saito NG, Paterson Y. Nuclear magnetic resonance spectroscopy for the study of B-cell epitopes. Methods. 1996 Jun;9(3):516–524. PubMed PMID: 8812707.
84. Wei H, Mo J, Tao L,et al. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today. 2014 Jan;19(1):95–102. PubMed PMID: 23928097; PubMed Central PMCID: PMC4081482.
85. Bergmann-Leitner ES, Chaudhury S, Steers NJ, et al. Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen. PloS One. 2013;8(8):e71610. PubMed PMID: 23977087; PubMed Central PMCID: PMC3745447.
86. Greenbaum JA, Andersen PH, Blythe M,et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit. 2007 Mar-Apr;20(2):75–82. PubMed PMID: 17205610.
87. Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol. 2007 Oct 02;7:64.
88. Caoili SE. Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects. J Biomed Biotechnol. 2010;2010:910524. PubMed PMID: 20368996; PubMed Central PMCID: PMC2847767.
89. Sirskyj D, Diaz-Mitoma F, Golshani A,et al. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol Cell Biol. 2011 Jan;89(1):81–89. PubMed PMID: 20458336.
90. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol. 1995;13:587–622. PubMed PMID: 7612235.
91. Harris PE. Self-peptides bound to HLA molecules. Crit Rev Immunol. 1994;14(1):61–87. PubMed PMID: 7741977.
92. Singh SP, Mishra BN. Major histocompatibility complex linked databases and prediction tools for designing vaccines. Hum Immunol. 2016 Mar;77(3):295–306. PubMed PMID: 26585361.
93. Karpenko O, Huang L, Dai Y. A probabilistic meta-predictor for the MHC class II binding peptides. Immunogenetics. 2008 Jan;60(1):25–36. PubMed PMID: 18092156.
94. Mallios RR. A consensus strategy for combining HLA-DR binding algorithms. Hum Immunol. 2003 Sep;64(9):852–856. PubMed PMID: 12941539.
95. Wang P, Sidney J, Dow C, et al. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008 Apr 04;4(4):e1000048. PubMed PMID: 18389056; PubMed Central PMCID: PMC2267221.
96. Townsend AR, Rothbard J, Gotch FM, et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986 Mar 28;44(6):959–968. PubMed PMID: 2420472.
97. Davenport MP, Hill AV. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol Med Today. 1996 Jan;2(1):38–45. PubMed PMID: 8796850.
98. De Groot AS, Bosma A, Chinai N, et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine. 2001 Aug 14;19(31):4385–4395. PubMed PMID: 11483263.
99. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol. 1998 Aug;10(4):478–482. PubMed PMID: 9722926.
100. Panina-Bordignon P, Demotz S, Corradin G, et al. Study on the immunogenicity of human class-II-restricted T-cell epitopes: processing constraints, degenerate binding, and promiscuous recognition. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):445–451. PubMed PMID: 2484166.
101. Panina-Bordignon P, Tan A, Termijtelen A,et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 Dec;19(12):2237–2242. PubMed PMID: 2481588.
102. Van Den Berg HA, Molina-Paris C, Sewell AK. Specific T-cell activation in an unspecific T-cell repertoire. Sci Prog. 2011;94(Pt3):245–264. PubMed PMID: 22026148.
103. Whitton JL, Sheng N, Oldstone MB, et al. A “string-of-beads” vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol. 1993 Jan;67(1):348–352. PubMed PMID: 7677954; PubMed Central PMCID: PMC237369.
104. An LL, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virol. 1997 Mar;71(3):2292–2302. PubMed PMID: 9032365; PubMed Central PMCID: PMC191338.
105. De Groot AS, Moise L, Liu R, et al. Immune camouflage: relevance to vaccines and human immunology. Hum Vaccin Immunother. 2014;10(12):3570–3575. PubMed PMID: 25483703; PubMed Central PMCID: PMC4514035.
106. Goldman M, Craft B, Swatloski T,et al. The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res. 2015 Jan;43(Database issue):D812–7. PubMed PMID: 25392408; PubMed Central PMCID: PMC4383911.
107. Klonowska K, Czubak K, Wojciechowska M, et al. Oncogenomic portals for the visualization and analysis of genome-wide cancer data. Oncotarget. 2016 Jan 05;7(1):176–192. PubMed PMID: 26484415; PubMed Central PMCID: PMC4807991.
108. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Reviews Clin Oncology. 2017 Oct 04;14:749–762. PubMed PMID: 28975929.
109. Li J, Lu Y, Akbani R,et al. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Nov;10(11):1046–1047. PubMed PMID: 24037243; PubMed Central PMCID: PMC4076789.
110. Xiong Y, Wei Y, Gu Y, et al. DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database. Nucleic Acids Res. 2017 Jan 04;45(D1):D888–895. PubMed PMID: 27899673; PubMed Central PMCID: PMC5210584.
111. Vaughan K, Xu X, Caron E, et al. Deciphering the MHC-associated peptidome: a review of naturally processed ligand data. Expert Rev Proteomics. 2017 Aug;11:1–8. PubMed PMID: 28756714.
112. He Y. Vaccine adjuvant informatics: from data integration and analysis to rational vaccine adjuvant design. Front Immunol. 2014;5:32. PubMed PMID: 24550916; PubMed Central PMCID: PMC3909948.
113. Gentile F, Deriu MA, Licandro G, et al. Structure based modeling of small molecules binding to the TLR7 by atomistic level simulations. Molecules. 2015 May 08;20(5):8316–8340. PubMed PMID: 26007168.
114. Savar NS, Bouzari S. In silico study of ligand binding site of toll-like receptor 5. Adv Biomed Res. 2014;3:41. PubMed PMID: 24627849; PubMed Central PMCID: PMC3949343.
115. Wu TY, Singh M, Miller AT, et al. Rational design of small molecules as vaccine adjuvants. Sci Transl Med. 2014 Nov 19;6(263):263ra160. PubMed PMID: 25411473.
116. Yu H, Jin H, Sun L, et al. Toll-like receptor 7 agonists: chemical feature based pharmacophore identification and molecular docking studies. PloS One. 2013;8(3):e56514. PubMed PMID: 23526932; PubMed Central PMCID: PMC3603940.
117. Zatsepin M, Mattes A, Rupp S, et al. Computational discovery and experimental confirmation of TLR9 receptor antagonist leads. J Chem Inf Model. 2016 Sep 26;56(9):1835–1846. PubMed PMID: 27537371.
118. Bayry J, Tchilian EZ, Davies MN, et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA. 2008 Jul 22;105(29):10221–10226. PubMed PMID: 18621704; PubMed Central PMCID: PMC2481334.
119. Davies MN, Bayry J, Tchilian EZ, et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PloS One. 2009 Nov 30;4(11):e8084. PubMed PMID: 20011659; PubMed Central PMCID: PMC2787246.
120. De Spiegeleer A, Wynendaele E, Vandekerckhove M, et al. An in silico approach for modelling T-helper polarizing iNKT cell agonists. PloS One. 2014;9(1):e87000. PubMed PMID: 24498010; PubMed Central PMCID: PMC3909045.
121. Pappalardo F, Fichera E, Paparone N, et al. A computational model to predict the immune system activation by citrus-derived vaccine adjuvants. Bioinformatics. 2016 Sep 01;32(17):2672–2680. PubMed PMID: 27162187.
122. Sayers S, Ulysse G, Xiang Z, et al. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol. 2012;2012:831486. PubMed PMID: 22505817; PubMed Central PMCID: PMC3312338.
123. He Y. Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert Rev Vaccines. 2014 Jul;13(7):825–841. PubMed PMID: 24909153; PubMed Central PMCID: PMC4815432.
124. Maertzdorf J, Kaufmann SH, Weiner J, 3rd. Molecular signatures for vaccine development. Vaccine. 2015 Sep 29;33(40):5256–5261. PubMed PMID: 25858856.
125. Nakaya HI, Li S, Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med. 2012 Mar-Apr;4(2):193–205. PubMed PMID: 22012654; PubMed Central PMCID: PMC3288517
126. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010 Oct 29;33(4):516–529. PubMed PMID: 21029962; PubMed Central PMCID: PMC3001343.
127. Grimm SK, Ackerman ME. Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol. 2013 Dec;24(6):1078–1088. PubMed PMID: 23474232; PubMed Central PMCID: PMC3696422.
128. Olafsdottir T, Lindqvist M, Harandi AM. Molecular signatures of vaccine adjuvants. Vaccine. 2015 Sep 29;33(40):5302–5307. PubMed PMID: 25989447.
129. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J. 2009 May;28(5):431–432. PubMed PMID: 19395950; PubMed Central PMCID: PMC2843136.
130. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2017 Jul 31. PubMed PMID: 28774561.
131. Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines. 2015 Jul;14(7):935–947. PubMed PMID: 25937189; PubMed Central PMCID: PMC4630804
132. Mueller AK, Labaied M, Kappe SH, et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005 Jan 13;433(7022):164–167. PubMed PMID: 15580261.
133. Moriel DG, Bertoldi I, Spagnuolo A, et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA. 2010 May 18;107(20):9072–9077. PubMed PMID: 20439758; PubMed Central PMCID: PMC2889118.
134. Rasko DA, Rosovitz MJ, Myers GS,et al. The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol. 2008 Oct;190(20):6881–6893. PubMed PMID: 18676672; PubMed Central PMCID: PMC2566221.
135. Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature. 1986 Aug 21–27;322(6081):747–748. PubMed PMID: 2427953.
136. Rubinstein ND, Mayrose I, Halperin D,et al. Computational characterization of B-cell epitopes. Mol Immunol. 2008 Jul;45(12):3477–3489. PubMed PMID: 18023478.
137. Rubinstein ND, Mayrose I, Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol Immunol. 2009 Feb;46(5):840–847. PubMed PMID: 18947876.
138. Van Regenmortel MH. Antigenicity and immunogenicity of synthetic peptides. Biologicals. 2001 Sep-Dec;29(3–4):209–213. PubMed PMID: 11851317.
139. Walter G. Production and use of antibodies against synthetic peptides. J Immunol Methods. 1986 Apr 17;88(2):149–161. PubMed PMID: 2420900.